In response to the global spread of COVID-19, the company mobilized to support the pandemic response with products and services for diagnosis, therapeutics and vaccines, while staying in close communication with its sites, employees, customers and suppliers and adopting preventive measures to maintain the safety and health of factory employees and preserve operational continuity amid travel restrictions and border closures that could significantly hamper its supply chain. Recognizing risks from natural disasters, public health crises, political turmoil and other external events, the company applies its practical process improvement (PPI) business system, global sourcing initiatives and low-cost region manufacturing to mitigate disruptions, allocates research and development funding to products with higher growth prospects, expands its service offerings, enhances geographic sales reach and e-commerce platforms, and combines sales and marketing operations to improve operational flexibility and resilience. The firm monitors reliance on sole or limited sources of supply and undertakes supplier qualification to reduce vulnerability, upgrades enterprise resource planning software to manage critical business operations, and maintains $10.33 billion of cash and cash equivalents along with available capacity under its $3.0 billion revolving credit facility to absorb strain and finance strategic initiatives. The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events or changes in circumstances indicate potential risks, integrating acquired businesses and optimizing asset value to preserve performance under adverse conditions.